USD 165.41
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| R | -0.1 | 6.2 | 2.1 | 10.4 | 22.8 | 50.8 | 113.4 | 199.0 | 86.7 | 3214.8 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | R |
| name | Ryder System, Inc. |
| price | 165.41 |
| changes percentage | -0.09 |
| change | -0.15 |
| day low | 164.44 |
| day high | 166.41 |
| year high | 171.78 |
| year low | 106.62 |
| market cap | 6995221982 |
| price avg 50 | 161.51 |
| price avg 200 | 138.75 |
| exchange | NYSE |
| volume | 980239 |
| avg volume | 287267 |
| open | 165.70 |
| previous close | 165.56 |
| eps | 10.68 |
| pe | 15.49 |
| earnings announcement | 2025-02-12T13:30:00.000+0000 |
| shares outstanding | 42290200 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000085961 | |||
| revenue | 11783000000 | 12461000000 | -5.44 |
| gross profit | 2299000000 | 2840000000 | -19.05 |
| gross profit ratio | 0.2 | 0.23 | -14.39 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 1421000000 | 1415000000 | 0.42 |
| interest income | 0 | 228000000 | -100.00 |
| interest expense | 296000000 | 228000000 | 29.82 |
| ebitda | 2932000000 | 3393000000 | -13.59 |
| ebitdaratio | 0.25 | 0.12 | 114.43 |
| operating income | 878000000 | -385000000 | 328.05 |
| operating income ratio | 0.07 | -0.03 | 341.17 |
| net income | 406000000 | 867000000 | -53.17 |
| net income ratio | 0.03 | 0.07 | -50.48 |
| eps | 9.2 | 17.4 | -47.13 |
Revenue Growth: revenue decreased to 11,783 million in 2023 from 12,461 million in 2022 representing a change of -5.44%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 2,299 million in 2023 from 2,840 million in 2022 representing a change of -19.05%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 1,421 million in 2023 from 1,415 million in 2022 representing a change of 0.42%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 2,932 million in 2023 from 3,393 million in 2022 representing a change of -13.59%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to 406 million in 2023 from 867 million in 2022 representing a change of -53.17%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 9.2 in 2023 from 9.2 in 2022 representing a change of -47.13%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Operating Income: Operating income increased to 878 million in 2023 from -385 million in 2022 representing a change of 328.05%. The increase in operating income indicates better operational performance and increased profitability.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000085961 | |||
| revenue | 3183000000 | 3182000000 | 0.03 |
| gross profit | 655000000 | 618000000 | 5.99 |
| gross profit ratio | 0.21 | 0.19 | 5.95 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 368000000 | 357000000 | 3.08 |
| interest income | 0 | 0 | NaN |
| interest expense | 98000000 | 96000000 | 2.08 |
| ebitda | 720000000 | 691000000 | 4.20 |
| ebitdaratio | 0.23 | 0.22 | 2.82 |
| operating income | 287000000 | 261000000 | 9.96 |
| operating income ratio | 0.09 | 0.08 | 9.93 |
| net income | 142000000 | 127000000 | 11.81 |
| net income ratio | 0.04 | 0.04 | 11.78 |
| eps | 3.32 | 2.89 | 14.88 |
Revenue Growth: revenue increased to 3,183 million in 2024Q3 from 3,182 million in 2024Q2 representing a change of 0.03%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 655 million in 2024Q3 from 618 million in 2024Q2 representing a change of 5.99%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 720 million in 2024Q3 from 691 million in 2024Q2 representing a change of 4.2%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 287 million in 2024Q3 from 261 million in 2024Q2 representing a change of 9.96%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 142 million in 2024Q3 from 127 million in 2024Q2 representing a change of 11.81%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 3.32 in 2024Q3 from 3.32 in 2024Q2 representing a change of 14.88%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 368 million in 2024Q3 from 357 million in 2024Q2 representing a change of 3.08%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000085961 | |||
| total assets | 15778000000 | 14395000000 | 9.61 |
| total liabilities | 12709000000 | 11458000000 | 10.92 |
| total equity | 3069000000 | 2937000000 | 4.49 |
| cash and cash equivalents | 204000000 | 267000000 | -23.60 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 2265000000 | 2200000000 | 2.95 |
| total non current assets | 13513000000 | 12195000000 | 10.81 |
| total current liabilities | 3649000000 | 1967000000 | 85.51 |
| total non current liabilities | 9060000000 | 9491000000 | -4.54 |
| common stock | 22000000 | 23000000 | -4.35 |
| retained earnings | 2554000000 | 2518000000 | 1.43 |
| total debt | 8148000000 | 7892000000 | 3.24 |
Total Assets: Total Assets increased to 15,778 million in 2023 from 14,395 million in 2022 representing a change of 9.61%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 3,069 million in 2023 from 2,937 million in 2022 representing a change of 4.49%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 2,265 million in 2023 from 2,200 million in 2022 representing a change of 2.95%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 2,554 million in 2023 from 2,518 million in 2022 representing a change of 1.43%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 12,709 million in 2023 from 11,458 million in 2022 representing a change of 10.92%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 204 million in 2023 from 267 million in 2022 representing a change of -23.6%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 3,649 million in 2023 from 1,967 million in 2022 representing a change of 85.51%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 22 in 2023 from 23 in 2022 representing a change of -4.35%. This indicates a decrease in ownership interest.
Total Debt: Total Debt increased to 8,148 million in 2023 from 7,892 million in 2022 representing a change of 3.24%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000085961 | |||
| total assets | 16497000000 | 16408000000 | 0.54 |
| total liabilities | 13441000000 | 13327000000 | 0.86 |
| total equity | 3056000000 | 3081000000 | -0.81 |
| cash and cash equivalents | 162000000 | 164000000 | -1.22 |
| short term investments | 0 | 0 | NaN |
| long term investments | 9091000000 | -1640000000 | 654.33 |
| total current assets | 2381000000 | 2371000000 | 0.42 |
| total non current assets | 14116000000 | 14037000000 | 0.56 |
| total current liabilities | 3211000000 | 3184000000 | 0.85 |
| total non current liabilities | 10230000000 | 10143000000 | 0.86 |
| common stock | 21000000 | 22000000 | -4.55 |
| retained earnings | 2577000000 | 2589000000 | -0.46 |
| total debt | 8757000000 | 8734000000 | 0.26 |
Total Assets: Total Assets increased to 16,497 million in 2024Q3 from 16,408 million in 2024Q2 representing a change of 0.54%. Suggesting a growth in asset holdings.
Total Current Assets: Total Current Assets increased to 2,381 million in 2024Q3 from 2,371 million in 2024Q2 representing a change of 0.42%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 13,441 million in 2024Q3 from 13,327 million in 2024Q2 representing a change of 0.86%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 3,056 million in 2024Q3 from 3,081 million in 2024Q2 representing a change of -0.81%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 162 million in 2024Q3 from 164 million in 2024Q2 representing a change of -1.22%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 3,211 million in 2024Q3 from 3,184 million in 2024Q2 representing a change of 0.85%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 21 in 2024Q3 from 22 in 2024Q2 representing a change of -4.55%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to 2,577 million in 2024Q3 from 2,589 million in 2024Q2 representing a change of -0.46%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 8,757 million in 2024Q3 from 8,734 million in 2024Q2 representing a change of 0.26%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000085961 | |||
| net change in cash | -63000000 | -405000000 | 84.44 |
| operating cash flow | 2353000000 | 2310000000 | 1.86 |
| free cash flow | -881000000 | -321000000 | -174.45 |
| capital expenditure | -3234000000 | -2631000000 | -22.92 |
| depreciation and amortization | 1814000000 | 1831000000 | -0.93 |
| deferred income tax | 115000000 | 266000000 | -56.77 |
| stock based compensation | 0 | 46000000 | -100.00 |
| accounts payables | -7000000 | -29000000 | 75.86 |
| inventory | 0 | -9000000 | 100.00 |
| acquisitions net | -250000000 | -458000000 | 45.41 |
| investments in property plant and equipment | -3234000000 | -2631000000 | -22.92 |
| net cash used for investing activites | -2663000000 | -1850000000 | -43.95 |
| debt repayment | 726000000 | -189000000 | 484.13 |
| common stock issued | 2000000 | 14000000 | -85.71 |
| common stock repurchased | -337000000 | -557000000 | 39.50 |
| dividends paid | -128000000 | -123000000 | -4.07 |
| net cash used provided by financing activities | 256000000 | -861000000 | 129.73 |
| cash at end of period | 204000000 | 267000000 | -23.60 |
| accounts receivables | -26000000 | -134000000 | 80.60 |
| cash at beginning of period | 267000000 | 672000000 | -60.27 |
Net Change in Cash: Net Change in Cash increased to -63 million in 2023 from -405 million in 2022 representing a change of 84.44%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 2,353 million in 2023 from 2,310 million in 2022 representing a change of 1.86%. This indicates that the company generated more cash from its core business operations.
Capital Expenditure: Capital Expenditure decreased to -3,234 million in 2023 from -2,631 million in 2022 representing a change of -22.92%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2023 from 46 million in 2022 representing a change of -100.0%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 7 million in 2023 from 29 million in 2022 representing a change of 75.86%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Free Cash Flow: Free Cash Flow decreased to -881 million in 2023 from -321 million in 2022 representing a change of -174.45%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Receivables: Accounts Receivables increased to -26 in 2023 from -134 million in 2022 representing a change of 80.6%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -128 million in 2023 from -123 million in 2022 representing a change of -4.07%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000085961 | |||
| operating cash flow | 629000000 | 552000000 | 13.95 |
| free cash flow | 31000000 | -86000000 | 136.05 |
| capital expenditure | -598000000 | -638000000 | 6.27 |
| depreciation and amortization | 460000000 | 439000000 | 4.78 |
| deferred income tax | -9000000 | -10000000 | 10.00 |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | -17000000 | -54000000 | 68.52 |
| accounts payables | 8000000 | -2000000 | 500.00 |
| inventory | 0 | 0 | NaN |
| acquisitions net | -16000000 | 144000000 | -111.11 |
| investments in property plant and equipment | -598000000 | -638000000 | 6.27 |
| net cash used for investing activites | -497000000 | -495000000 | -0.40 |
| debt repayment | 43000000 | -17000000 | 352.94 |
| common stock issued | 6000000 | 0 | NaN |
| common stock repurchased | -141000000 | -73000000 | -93.15 |
| dividends paid | -35000000 | -31000000 | -12.90 |
| net cash used provided by financing activities | -129000000 | -122000000 | -5.74 |
| net change in cash | -2000000 | -70000000 | 97.14 |
| cash at end of period | 162000000 | 164000000 | -1.22 |
| cash at beginning of period | 164000000 | 234000000 | -29.91 |
Net Change in Cash: Net Change in Cash increased to -2 million in 2024Q3 from -70 million in 2024Q2 representing a change of 97.14%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 629 million in 2024Q3 from 552 million in 2024Q2 representing a change of 13.95%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 31 million in 2024Q3 from -86 million in 2024Q2 representing a change of 136.05%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -598 million in 2024Q3 from -638 million in 2024Q2 representing a change of 6.27%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -9 million in 2024Q3 from -10 million in 2024Q2 representing a change of 10.0%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 8 million in 2024Q3 from 2 million in 2024Q2 representing a change of 500.0%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -17 in 2024Q3 from -54 million in 2024Q2 representing a change of 68.52%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -35 million in 2024Q3 from -31 million in 2024Q2 representing a change of -12.9%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 268.39 | 251.49 | 6.72 |
| net income per share | 9.25 | 17.5 | -47.15 |
| operating cash flow per share | 53.6 | 46.62 | 14.96 |
| free cash flow per share | -20.07 | -6.48 | -209.76 |
| cash per share | 4.65 | 5.39 | -13.77 |
| book value per share | 69.91 | 59.27 | 17.94 |
| tangible book value per share | 39.47 | 35.94 | 9.82 |
| shareholders equity per share | 69.91 | 59.27 | 17.94 |
| interest debt per share | 192.34 | 163.88 | 17.37 |
| market cap | 5051371598.9 | 4140809930.0 | 21.99 |
| enterprise value | 12995371598.9 | 11765809930 | 10.45 |
| pe ratio | 12.44 | 4.78 | 160.51 |
| price to sales ratio | 0.43 | 0.33 | 29.01 |
| pocfratio | 2.15 | 1.79 | 19.76 |
| pfcf ratio | -5.73 | -12.9 | 55.55 |
| pb ratio | 1.65 | 1.41 | 16.74 |
| ptb ratio | 1.65 | 1.41 | 16.74 |
| ev to sales | 1.1 | 0.94 | 16.81 |
| enterprise value over ebitda | 4.43 | 3.47 | 27.82 |
| ev to operating cash flow | 5.52 | 5.09 | 8.43 |
| ev to free cash flow | -14.75 | -36.65 | 59.76 |
| earnings yield | 0.08 | 0.21 | -61.61 |
| free cash flow yield | -0.17 | -0.08 | -124.98 |
| debt to equity | 2.65 | 2.69 | -1.20 |
| debt to assets | 0.52 | 0.55 | -5.81 |
| net debt to ebitda | 2.71 | 2.25 | 20.56 |
| current ratio | 0.62 | 1.12 | -44.50 |
| interest coverage | 2.97 | -1.69 | 275.66 |
| income quality | 5.8 | 2.68 | 116.52 |
| dividend yield | 0.03 | 0.03 | -14.69 |
| payout ratio | 0.32 | 0.14 | 122.23 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.08 | 0.08 | 5.44 |
| capex to operating cash flow | 1.37 | 1.14 | 20.67 |
| capex to revenue | 0.27 | 0.21 | 29.99 |
| capex to depreciation | 1.78 | 1.44 | 24.07 |
| stock based compensation to revenue | 0 | 0.0 | -100.00 |
| graham number | 120.61 | 152.76 | -21.05 |
| roic | 0.04 | -0.02 | 311.19 |
| return on tangible assets | 0.03 | 0.07 | -57.07 |
| graham net net | -255.56 | -200.7 | -27.33 |
| working capital | -1384000000 | 233000000 | -693.99 |
| tangible asset value | 1733000000 | 1781000000 | -2.70 |
| net current asset value | -10444000000 | -9258000000 | -12.81 |
| invested capital | 10909000000 | 10727000000 | 1.70 |
| average receivables | 1662000000 | 1537368500 | 8.11 |
| average payables | 800000000 | 757449000 | 5.62 |
| average inventory | 39000000 | 73338500 | -46.82 |
| days sales outstanding | 53.09 | 47.16 | 12.59 |
| days payables outstanding | 32.06 | 29.1 | 10.17 |
| days of inventory on hand | 0 | 2.96 | -100.00 |
| receivables turnover | 6.87 | 7.74 | -11.18 |
| payables turnover | 11.39 | 12.54 | -9.23 |
| inventory turnover | 0 | 123.35 | -100.00 |
| roe | 0.13 | 0.3 | -55.19 |
| capex per share | 73.66 | 53.1 | 38.73 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 12.44 on 2023-12-31 from 4.78 on 2022-12-31, representing a change of 160.51%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.62 on 2023-12-31 from 1.12 on 2022-12-31, representing a change of -44.50%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 2.65 on 2023-12-31 from 2.69 on 2022-12-31, representing a change of -1.20%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. However, a ratio of 2.0 or higher is usually considered risky.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| R | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 74.49 | 72.97 | 2.09 |
| net income per share | 3.32 | 2.91 | 14.11 |
| operating cash flow per share | 14.72 | 12.66 | 16.29 |
| free cash flow per share | 0.73 | -1.97 | 136.79 |
| cash per share | 3.79 | 3.76 | 0.81 |
| book value per share | 71.52 | 70.65 | 1.23 |
| tangible book value per share | 33.93 | 33.85 | 0.26 |
| shareholders equity per share | 71.52 | 70.65 | 1.23 |
| interest debt per share | 207.23 | 202.48 | 2.34 |
| market cap | 6230179800.0 | 5350388210 | 16.44 |
| enterprise value | 14825179800 | 13920388210 | 6.50 |
| pe ratio | 10.97 | 10.53 | 4.14 |
| price to sales ratio | 1.96 | 1.68 | 16.41 |
| pocfratio | 9.9 | 9.69 | 2.19 |
| pfcf ratio | 200.97 | -62.21 | 423.04 |
| pb ratio | 2.04 | 1.74 | 17.40 |
| ptb ratio | 2.04 | 1.74 | 17.40 |
| ev to sales | 4.66 | 4.37 | 6.47 |
| enterprise value over ebitda | 20.59 | 20.15 | 2.21 |
| ev to operating cash flow | 23.57 | 25.22 | -6.54 |
| ev to free cash flow | 478.23 | -161.86 | 395.45 |
| earnings yield | 0.02 | 0.02 | -3.98 |
| free cash flow yield | 0.0 | -0.02 | 130.96 |
| debt to equity | 2.87 | 2.83 | 1.08 |
| debt to assets | 0.53 | 0.53 | -0.28 |
| net debt to ebitda | 11.94 | 12.4 | -3.75 |
| current ratio | 0.74 | 0.74 | -0.42 |
| interest coverage | 2.93 | 2.72 | 7.72 |
| income quality | 4.43 | 4.42 | 0.31 |
| dividend yield | 0.01 | 0.01 | -3.04 |
| payout ratio | 0.25 | 0.24 | 0.98 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.1 | 0.1 | -0.48 |
| capex to operating cash flow | 0.95 | 1.16 | -17.74 |
| capex to revenue | 0.19 | 0.2 | -6.30 |
| capex to depreciation | 1.3 | 1.45 | -10.55 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 73.13 | 68.04 | 7.47 |
| roic | 0.01 | 0.01 | 18.55 |
| return on tangible assets | 0.01 | 0.01 | 11.15 |
| graham net net | -277.95 | -269.84 | -3.01 |
| working capital | -830000000 | -813000000 | -2.09 |
| tangible asset value | 1450000000 | 1476000000 | -1.76 |
| net current asset value | -11060000000 | -10956000000 | -0.95 |
| invested capital | 3070000000 | 12112000000 | -74.65 |
| average receivables | 1865000000 | 1837500000 | 1.50 |
| average payables | 844000000 | 825500000 | 2.24 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 52.85 | 52.64 | 0.40 |
| days payables outstanding | 31.72 | 27.98 | 13.39 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 1.7 | 1.71 | -0.40 |
| payables turnover | 2.84 | 3.22 | -11.81 |
| inventory turnover | 0 | 0 | NaN |
| roe | 0.05 | 0.04 | 12.73 |
| capex per share | 13.99 | 14.63 | -4.34 |
ROE: Return on Equity (ROE) increased to 0.05 on 2024-09-30 Q3 from 0.04 on 2024-06-30 Q2, representing a change of 12.73%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 0.74 on 2024-09-30 Q3 from 0.74 on 2024-06-30 Q2, representing a change of -0.42%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 2.87 on 2024-09-30 Q3 from 2.83 on 2024-06-30 Q2, representing a change of 1.08%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 10.97 on 2024-09-30 Q3 from 10.53 on 2024-06-30 Q2, representing a change of 4.14%. Indicating an increase in the relative valuation of the company's stock.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 09:25:00
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN® the highest possible recommendation (Grade I, A,1) via their practice guidelines.
Sentiment: Positive
Publish Date: 2025-01-16 09:00:00
The documentary, from Bad Robot, Glen Powell's Barnstorm Productions, Zipper Bros Films, IMAX Entertainment and Dolphin Entertainment reached over $2 million at the box office and was #1 on Prime Video when it was first released last summer MIAMI, FL / ACCESS Newswire / January 16, 2025 / The Blue Angels have been enthralling people across the country and around the globe for more than 75 years. IMAX Entertainment and Dolphin Entertainment (NASDAQ:DLPN) proudly present a thrilling new 3D version of the documentary "The Blue Angels" taking audiences soaring with the Navy's elite Flight Demonstration Squadron.
Sentiment: Positive
Publish Date: 2025-01-14 17:00:00
HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and high-quality result to be used in any health care setting.
Sentiment: Negative
Publish Date: 2025-01-14 09:10:00
Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®. The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.
Sentiment: Negative
Publish Date: 2025-01-14 09:00:00
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / General Enterprise Ventures, Inc. (OTC PINK:GEVI), a pioneer in the future of sustainable fire protection solutions, and its subsidiary, Mighty Fire Breaker®, LLC (MFB), extends their deepest sympathies to those affected by the recent Los Angeles wildfires. In response, we are launching a charitable initiative to support the impacted communities beginning with the donation of our patented, EPA-certified fire inhibitor, CitroTech®, to homeowners in high-risk areas, providing enhanced protection against future fire threats.
Sentiment: Positive
Publish Date: 2025-01-14 06:55:00
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions, expects to issue its fourth quarter 2024 results at approximately 7:00 a.m. Eastern Time on Wednesday, February 12, 2025. The company will also host a conference call at 11 a.m. Eastern Time on the same day. The call will be webcast live and a replay will be available. Details for the call include: When: Wednesday, February 12, 2025, from 11:00 a.m. to 12:00.
Sentiment: Positive
Publish Date: 2025-01-09 18:00:00
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led by REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto) with funding from the Canadian Institute of Health Research (CIHR) and Indigenous Services Canada (ISC).
Sentiment: Positive
Publish Date: 2025-01-09 14:33:29
Ryder System's shares have surged significantly, outperforming the S&P 500, and remain attractively priced, justifying a continued 'buy' rating. The company's revenue and operating revenue have shown consistent growth, driven by its Fleet Management, Supply Chain, and Dedicated Transportation Solutions segments. Despite mixed profitability, Ryder's operating cash flow and EBITDA have generally increased, with promising forecasts for 2024.
Sentiment: Positive
Publish Date: 2025-01-09 08:00:00
LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.
Sentiment: Positive
Publish Date: 2025-01-07 06:30:00
License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States. Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.
Sentiment: Negative
Publish Date: 2025-01-03 12:26:14
R is grappling with a downturn in freight market conditions, hurting its prospects. Escalated operating expenses are a major headwind.
Sentiment: Negative
Publish Date: 2024-12-26 07:00:00
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Sentiment: Positive
Publish Date: 2024-12-24 12:00:00
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and syphilis in Canada. The single Reveal® TP (Syphilis) approval will follow soon after this more complex approval.
Sentiment: Positive
Publish Date: 2024-12-23 06:30:00
With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum.
Sentiment: Positive
Publish Date: 2024-12-17 08:00:00
Deptec's plasma spectrometer is primed to play an integral role in the booming semiconductor manufacturing and thin-film sectors. SAN DIEGO, CA / ACCESSWIRE / December 17, 2024 / Dalrada Financial Corporation (OTC PINK:DFCO), "Dalrada," "the Company"), announced today that Spectroptix®, a proprietary advanced plasma spectrometer developed by its subsidiary, Deposition Technology ("Deptec,"), is now available for advance ordering.
Sentiment: Positive
Publish Date: 2024-12-16 16:35:00
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder appoints industry and company veterans to top operations and financial roles, naming chief operating officer and new chief financial officer.
Sentiment: Positive
Publish Date: 2024-12-12 03:01:00
Arlington, Virginia--(Newsfile Corp. - December 12, 2024) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5I) ("edgeTI", "Company"), a leading provider of real-time Digital Operations software that create Digital Twins that enable AI and other digital innovations, announced that it was recognized as a Representative Vendor in the newly published Gartner® Market Guide for Digital Twin of an Organization Platforms" report. edgeTI™ believes that the Company was identified for its focus on the operational excellence use case, followed by the manufacturing/supply chain and business performance management use cases.
Sentiment: Positive
Publish Date: 2024-12-11 08:15:00
Brisbane, Queensland, Australia--(Newsfile Corp. - December 11, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR® Powered by GMG Graphene.
Sentiment: Positive
Publish Date: 2024-12-11 06:55:04
Neos S&P 500(R) High Income ETF BATS: SPYI is an interesting play on the S&P 500 benchmarked to the CBOE's S&P 500 Buy-Write index. The Buy-Write index tracks potential returns from an S&P 500-oriented covered call strategy, which is the SPYI's primary focus.
Sentiment: Positive
Publish Date: 2024-12-10 08:19:00
Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Protium Clean Energy Corp. (CSE: GRUV) (FSE: G071), a leading resource company focused on clean energy and sustainable resource development, is pleased to announce that it has appointed John Ryder, P.Geo to its advisory board. Mr. Ryder has been engaged in mineral exploration worldwide for over 40 years exploring for a variety of commodities and gems as both a geologist and as management of public companies.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
